Catalent, Inc. Company Profile

Background

Overview

Catalent, Inc. is a leading global Contract Development and Manufacturing Organization (CDMO) specializing in drug delivery technologies, drug development, drug manufacturing, biologics, gene therapy, and consumer health products. Headquartered in Tampa, Florida, the company operates over 50 facilities across four continents, employing approximately 17,000 people, including more than 3,000 scientists and technicians. Catalent produces nearly 70 billion doses of approximately 8,000 products annually, serving over 1,000 customers worldwide.

Mission and Vision

• Mission: To develop, manufacture, and supply products that help people live better and healthier lives.

• Vision: To be the world’s most trusted, reliable, and innovative drug development and delivery partner by upholding the highest industry standards and exceeding customer expectations, while driving strong, sustained growth for the company.

Industry Significance

Catalent plays a vital role in the pharmaceutical industry, contributing to over half of FDA-approved products in the last decade. The company has been instrumental in accelerating over 1,500 partner development programs annually and launching over 150 new products each year.

Key Strategic Focus

Core Objectives

Catalent focuses on providing comprehensive solutions across the drug development lifecycle, from early-stage design to commercial manufacturing, ensuring seamless technology transfers, reliable outcomes, and the highest standards of quality.

Areas of Specialization

• Drug Delivery Technologies: Innovative platforms such as Zydis® fast-dissolve tablets and OptiGel® softgel capsules.

• Biologics and Gene Therapy: Advanced manufacturing capabilities for monoclonal antibodies and gene therapies.

• Consumer Health Products: Development and manufacturing of over-the-counter medications, nutritional supplements, and topical skin care products.

Key Technologies Utilized

• Zydis® Fast-Dissolve Tablets: A delivery system that dissolves in approximately three seconds without water.

• GPEx® Cell Line Development: A technology used in over 50 clinical trials and 10 commercially approved products for rapid creation of high-yielding cell lines for biologics manufacturing.

• SMARTag™ Bioconjugation Platform: Enables site-specific, controlled drug-protein conjugations for antibody-drug conjugates.

Primary Markets Targeted

Catalent serves pharmaceutical, biotechnology, and consumer health companies globally, ranging from small virtual organizations to large multinational corporations. Major clients include Bayer, Bristol-Myers Squibb, GlaxoSmithKline, Haleon, Novo Nordisk, Moderna, Pfizer, and Sarepta Therapeutics.

Financials and Funding

Funding History

Catalent went public in July 2014, raising approximately $870 million through its initial public offering on the New York Stock Exchange under the ticker symbol CTLT.

Recent Funding and Acquisition

In February 2024, Novo Holdings A/S, the parent company of Novo Nordisk, agreed to acquire Catalent for approximately $16.5 billion in cash. This acquisition was completed in December 2024, marking the end of Catalent’s decade-long presence as a publicly traded company.

Utilization of Capital

The acquisition by Novo Holdings A/S is expected to enhance Catalent's manufacturing capabilities, particularly in supporting the production of Novo Nordisk's products, including Wegovy and Ozempic.

Pipeline Development

Key Pipeline Candidates

Catalent's pipeline includes a diverse range of products across various therapeutic areas, including biologics, gene therapies, and consumer health products. The company collaborates with numerous partners to accelerate the development and manufacturing of these products.

Stages of Development

Catalent supports over 1,500 partner development programs annually, encompassing early-stage design, clinical trials, and commercial manufacturing. The company has been instrumental in launching over 150 new products each year.

Target Conditions

The company's pipeline addresses a wide array of conditions, including chronic diseases, rare disorders, and consumer health needs, reflecting its commitment to improving patient outcomes across diverse therapeutic areas.

Anticipated Milestones

Catalent's strategic focus on innovation and quality positions it to achieve significant milestones in product development and manufacturing, contributing to the advancement of healthcare solutions globally.

Technological Platform and Innovation

Proprietary Technologies

• Zydis® Fast-Dissolve Tablets: A delivery system that dissolves in approximately three seconds without water.

• GPEx® Cell Line Development: A technology used in over 50 clinical trials and 10 commercially approved products for rapid creation of high-yielding cell lines for biologics manufacturing.

• SMARTag™ Bioconjugation Platform: Enables site-specific, controlled drug-protein conjugations for antibody-drug conjugates.

Significant Scientific Methods

• Particle Size Reduction: Techniques such as spray drying and hot melt extrusion to enhance bioavailability.

• Lipid-Based Drug Delivery Systems: Utilized to improve the solubility and absorption of poorly water-soluble compounds.

AI-Driven Capabilities

While specific AI-driven capabilities are not detailed, Catalent's commitment to innovation suggests ongoing efforts to integrate advanced technologies into its development and manufacturing processes.

Leadership Team

Executive Profiles

• Alessandro Maselli: President and Chief Executive Officer since July 2022. Previously served as President & Chief Operating Officer from February 2019. Joined Catalent in 2010, holding various roles including Director of Operations and General Manager of Zydis® operations.

• Tom Hawkeswood: Senior Vice President, Global Operations since September 2025. Leads global operations with over 25 years of experience across multiple industries and contract manufacturing environments. Joined Catalent in 2017 as Vice President and General Manager of Canadian softgel sites.

Leadership Changes

In July 2022, Catalent underwent a significant organizational restructuring, consolidating from four reporting segments to two: Biologics and Pharma and Consumer Health. Alessandro Maselli was appointed President and CEO, succeeding John Chiminski, who transitioned to Executive Chair.

Competitor Profile

Market Insights and Dynamics

The global CDMO market is characterized by rapid growth, driven by increasing demand for outsourced development and manufacturing services, particularly in biologics and gene therapies. Catalent competes with major CDMOs such as Thermo Fisher Scientific, Lonza Group, and WuXi Biologics.

Competitor Analysis

• Thermo Fisher Scientific: A leading CDMO offering a comprehensive range of services, including drug development, clinical trials, and biologics manufacturing.

• Lonza Group: Specializes in pharmaceutical, biotech, and nutrition solutions, with a strong focus on biotechnology and cell and gene therapy solutions.

• WuXi Biologics: Provides end-to-end solutions for biologics discovery, development, and manufacturing, with a global presence and extensive capabilities.

Strategic Collaborations and Partnerships

Catalent has established significant collaborations with pharmaceutical and biotechnology companies, including partnerships to provide manufacturing, vial filling, and packaging capabilities for COVID-19 vaccines. In 2021, the company acquired Bettera Holdings for $1 billion to expand into nutritional supplements, and in 2022, acquired Metrics Contract Services for $475 million to enhance oral dosage form capabilities.

Operational Insights

Catalent's extensive global footprint and integrated service offerings provide a competitive advantage, enabling the company to meet diverse client needs across various therapeutic areas. The company's focus on innovation and quality positions it as a trusted partner in the pharmaceutical and biotechnology industries.

Strategic Opportunities and Future Directions

Strategic Roadmap

Catalent's strategic roadmap includes expanding its capabilities in biologics, gene therapy, and consumer health products, leveraging its proprietary technologies and global manufacturing network to support the development and commercialization of complex therapies.

Future Business Directions

The company aims to enhance its position in the CDMO market by investing in advanced technologies, expanding its global footprint, and fostering strategic partnerships.